The influence of graft composition on the outcome of reduced-intensity (RIC) allogeneic PBSC transplantation (allo-PBSC) remains controversial. In this study, we analyzed the impact of CD34 þ cell dose on the incidence of GVHD, and on the outcome after allo-PBSC, in 103 patients with hematological malignancies, using a uniform RIC regimen. The following variables were included in statistical analysis: (1) number of C34 þ cells, (2) highrisk vs low-risk disease status, (3) matched related vs matched unrelated donor, (4) female donor to male recipient vs any other combination, (5) age of recipient (above vs below the median). Univariate and multivariate analysis did not reveal any association between CD34 þ cell dose and acute grade-2 to grade-4, cGVHD, nonrelapse mortality (NRM), relapse rate (RR) and OS. High-risk disease status was the only variable independently associated with increased NRM (P ¼ 0.001), increased RR (P ¼ 0.012) and decreased OS (Po0.001). The same results were obtained when analysis was restricted to a subgroup of 55 patients with myeloid neoplasms. The influence of graft composition on the outcome of RIC allo-PBSC should be further investigated via well-controlled randomized prospective studies.
Introduction
Allogeneic PBSCs, mobilized in healthy donors after cytokine stimulation, have been introduced into the clinical field of allo-SCT in the last decade. 1 Compared with bone marrow (BM) grafts, PBSC contain significantly more CD34 þ hematopoietic stem cells, as well as 1 log more T-lymphocytes. 2 Although allogeneic PBSC is associated with faster myeloid and immune reconstitution, concerns about the incidence of chronic GVHD (cGVHD) and the associated related morbidity and mortality still exist, especially for patients with low-risk diseases and low probability of relapse post-transplantation. Most of the published studies showed that allo-SCT with the use of PBSC as opposed to BM, is associated with a similar rate of acute GVHD (aGVHD), but an increased incidence of cGVHD. [1] [2] [3] [4] [5] [6] [7] Moreover, in accordance with these data, some studies also show better OS and disease-free survival (DFS) among patients with advanced leukemia after allogeneic PBSC transplantation (allo-PBSC). 4, 8 This association has been explained mostly by the decreased incidence of relapse in patients with GVHD.
The development of reduced-intensity (RIC) or nonmyeloablative conditioning (NST) in preparation for SCT revolutionized the field and resulted in the extended application of transplant procedures to patients previously considered not suitable candidates because of age or concurrent co-morbidities. 9 The introduction of RIC or NST regimens in clinical practice contributed to the increased use of PBSC, since in most reported studies of allogeneic RIC, PBSC are the preferred source of stem cells.
The influence the 'cell dose' contained in the graft has on the transplant outcome has been the subject of many previous studies. In autologous and syngeneic, as well as in allogeneic BM transplantation, published studies show that infusion of higher numbers of hematopoietic cells is associated with improved transplant outcomes. [10] [11] [12] However, the influence of graft composition in the setting of allogeneic PBSC remains more controversial.
In the present study, we analyzed the influence of CD34 þ cell dose on the incidence of aGVHD and cGVHD, as well as on transplant outcome, after allo-SCT with the use of a uniform RIC regimen in a cohort of 103 patients with various hematological malignancies.
Patients and methods

Patients
In this study, we included 103 patients with malignant diseases, referred to the department of Bone Marrow Transplantation and Cancer Immunotherapy of Hadassah University Hospital in Jerusalem between 1997 and 2005, and treated with the same RIC regimen. Patient characteristics are shown in Table 1 .
Transplantation procedure
Conditioning regimen consisted of fludarabine (30 mg/m 2 / day Â 6), oral BU (4 mg/kg/day) (or i.v. busulfex, 3.2 mg/ kg/day Â 2) and ATG (Fresenius, Bad Homburg, Germany) (10 mg/kg/day Â 4). Oral BU was given to 48 patients, while 55 patients were treated with the intravenous formulation. GVHD prophylaxis consisted of CYA, with an initial i.v. dose of 3 mg/kg or equivalent oral dose of 6 mg/kg, with subsequent control of serum levels and renal function tests, initially from day À1 and subsequently from day À4.
Donors
The donors were HLA-identical siblings in 74 cases and matched unrelated donors in 29 cases. Unrelated donors were high-resolution HLA-A, B, C and DRB1-matched (8 out of 8 alleles) with their respective recipients. PBSC was the source of stem cells for all 103 patients. For PBSC collection, donors were injected subcutaneously with granulocyte colony-stimulating factor (Neupogen, Thousand Oaks, CA, USA; 5 mg/kg twice daily for 5 days) and mobilized PBSCs were collected on days 5 and 6.
CD34 þ cell counting
The absolute number of CD34 þ cells was measured in samples of leukapheresis products. After erythrocyte lysis, cells were stained with an anti-CD34 monoclonal antibody conjugated with phycoerythrin and analyzed by flow cytometry. A side-scatter/CD34-phycoerythrin live gate was performed in which only cells with high intensity of phycoerythrin fluorescence were selected. Then the cluster of CD34 þ cells, among these events around the lowintermediate side scatter, was selected. The proportion of CD34 þ cells was estimated and the absolute count of CD34 þ cells per microliter was calculated by multiplying the proportion of CD34 cells by the total WBC count.
Definitions
The day of neutrophil engraftment was defined as the first of three consecutive days with ANC40.5 Â 10 9 /l. The day of platelet engraftment was defined as the first of three days with platelets (PLT)420 Â 10 9 /l without any transfusion support. For diagnosis and staging of aGVHD and cGVHD, standard previously published criteria were used. 13, 14 All patients who had a successful engraftment and survived for at least 4 weeks were evaluable for aGVHD analysis, while patients who survived for at least 100 days were evaluable for cGVHD analysis. Patients were stratified into high-or low-risk categories according to their disease status pre-transplant. More specifically, patients with AML or ALL in the first complete remission, CML in the first chronic phase, myelodysplastic syndrome (MDS) without excess of blasts (RA or RARS), non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) or multiple myeloma (MM) without chemorefractory disease were classified as low-risk patients. All other patients were classified as high-risk patients. 15, 16 Statistical analysis The primary endpoint of this retrospective study was to analyze the correlation between the number of CD34 þ cells infused with the graft and the actuarial probability to develop aGVHD or cGVHD. The secondary endpoint was to analyze the correlation between the number of CD34 þ cells infused and OS, non-relapse mortality (NRM) and relapse. OS was defined as the time from the day of transplant to death from any cause, or the last follow-up. Time to NRM was defined as the time from the day of transplant until death from any cause not associated with the original disease, or the last follow-up. Time to relapse was defined as the time from the date of transplant until recurrence of the malignant disorder, or the last follow-up. 
Results
Characteristics of the graft inoculum
The CD34 þ cell dose was available for all the 103 patients, while CD3 þ cell dose was available for 65 of the patients included in this study. A median of 10 Â Impact of graft composition on aGVHD and cGVHD Overall, 45 patients developed aGVHD. The cumulative incidence of aGVHD grade-2 to 4 and grade-3 to 4 was 35 and 20%, respectively. cGVHD was observed in 32 out of 75 evaluable patients for a cumulative incidence of 43%. The incidence of extensive cGVHD was 23%.
We analyzed more specifically the influence of CD34 þ cell dose on the incidence and severity of aGVHD and cGVHD. Patients were divided into two groups depending on whether the infused CD34 þ cell dose was above or below the median (10 Â 10 6 /kg). No difference in the incidence and severity of grade-2 to 4 aGVHD (P ¼ 0.712) and cGVHD (P ¼ 0.135) ( Figure 1 ) was observed between the two groups of patients.
To further examine whether there is any impact of the infused CD34 þ cell dose on the incidence of GVHD, we divided our patients in three groups. Group 1 included 25% of the total number of patients who received less than 6.1 Â 10 6 /kg (below the 25th percentile) CD34 þ cells. Group 2 included 25% of the patients who received more than 15.5 Â 10 6 /kg (above the 75th percentile) CD34 þ cells. Group 3 included 75% of the patients who received more than 6.1 Â 10 6 /kg (above the 25th percentile) CD34 þ cells. No significant differences in the incidence and severity of aGVHD grade-2 to 4 and cGVHD was observed between the patients in groups 1 and 2 (P ¼ 0.103, and P ¼ 0.451, respectively) (data not shown). Also, patients who received less than 6.1 Â 10 6 /kg CD34 þ cells (group 1, below the 25th percentile) did not differ significantly in terms of acute grade-2 to 4 (P ¼ 0.363) and cGVHD (P ¼ 0.879), in comparison with patients who received more than 6.1 Â 10 6 /kg CD34 þ cells (group 3, above the 25th percentile).
In order to exclude any effect because of imbalance in prognostic variables between the cohorts, regression analysis was performed. The following categorical variables were included in Cox-proportional regression: (1) female donor to male recipient (yes vs no), (2) disease risk status (high risk vs low), (3) related donor vs unrelated, (4) age of recipient (below vs above the median) and (5) number of CD34 þ cells (below vs above the median). Multivariate analysis of the prognostic variables for the development of aGVHD grade-2 to 4 and cGVHD did not show any statistical significance (Table 2) . To further examine whether there is any impact of the infused CD34 þ cell dose on the incidence of GVHD, a second regression analysis was performed using the same variables except that the number of CD34 þ cells was included as a categorical variable, but with a different cut-off point (below or above the 25th percentile). Multivariate analysis did not reveal any statistical significance (data not shown).
Impact of graft composition on OS, NRM and RR
With a median follow-up period of 36 months (range 1-139 months) 44 out of 103 patients were alive with an OS rate of 43%. Thirty out of 103 patients died from causes not associated with the original disease, while relapse was observed in 29 patients. The estimated NRM and RR were 30 and 29%, respectively. OS, NRM and RR were similar between patients infused with CD34 þ cells above or below the median (10 Â 10 6 /kg) (P ¼ 0.331 0.640 and 0.375, respectively). Graft composition in RIC P Tsirigotis et al
To further examine whether there is any impact of the infused CD34 þ cell dose on the outcome after allo-SCT in terms of OS, NRM and RR, we divided our patients into three groups as described previously (group 1, 2 and 3).
Patients who received less than 6.1 Â 10 6 /kg CD34 þ cells (group 1, below the 25th percentile) did not differ significantly in terms of OS (P ¼ 0.126), NRM (P ¼ 0.392) and RR (P ¼ 0.139) from patients in group 2 (CD34 þ cell dose above the 75th percentile). Also patients in group 1 (CD34 þ cell dose below the 25th percentile) did not differ significantly in terms of OS (P ¼ 0.059), NRM (P ¼ 0.612) and RR (P ¼ 0.072) from patients in group 3 (CD34 þ cell dose above the 25th percentile).
Multivariate analysis did not demonstrate independent prognostic significance of any of the following risk factors (female donor to male recipient, related vs unrelated donor, age and number of CD34 þ cells) regarding the incidence of OS, NRM and RR (data not shown). However, multivariate analysis demonstrated the independent prognostic significance of 'disease risk status' as a risk factor for increased NRM (P ¼ 0.001), increased RR (P ¼ 0.012) and decreased OS (Po0.001).
Subgroup of patients with myeloid neoplasms: the impact of graft composition on aGVHD and cGVHD Fifty-five out of 103 patients underwent allo-SCT for treatment of various myeloid neoplasms. Patient characteristics are shown in Table 1 . Overall, 12 out of 55 patients developed aGVHD. The cumulative incidence of aGVHD grade-2 to 4 and grade-3 to 4 was 23 and 19%, respectively. cGVHD was observed in 17 out of 45 evaluable patients for a cumulative incidence of 40%. The incidence of extensive cGVHD was 21%.
We analyzed more specifically the influence of CD34 þ cell dose on the incidence and severity of aGVHD grade-2 to 4 and cGVHD. Patients were divided into two groups depending on whether the infused CD34 þ cell dose was above or below the median (10.4 Â 10 6 /kg). No difference in the incidence and severity of aGVHD grade-2 to 4 (P ¼ 0.938) and cGVHD (P ¼ 0.076) (Figure 2 ) was observed between the two groups of patients.
To further examine whether there is any impact of the infused CD34 þ cell dose on the incidence of GVHD, we divided our patients into three groups. Group 1 included 25% of the total number of patients who received less than 4.67 Â 10 6 /kg (below the 25th percentile) CD34 þ cells. Group 2 included 25% of the patients who received more than 15.1 Â 10 6 /kg (above the 75th percentile) CD34 þ cells. Group 3 included 75% of the patients who received more than 4.67 Â 10 6 /kg (above the 25th percentile) CD34 þ cells. No significant differences in the incidence and severity of aGVHD grade-2 to 4 and cGVHD was observed between the patients in groups 1 and 2 (P ¼ 0.305 and 0.467, respectively) (data not shown). Also, patients who received less than 4.67 Â 10 6 /kg CD34 þ cells (group 1, below the 25th percentile) did not differ significantly in terms of aGVHD grade-2 to 4 (P ¼ 0.422) and cGVHD (P ¼ 0.917) from patients who received more than 4.67 Â 10 6 /kg CD34 þ cells (group 3, above the 25th percentile). 
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In order to exclude any effect because of an imbalance in prognostic variables between the cohorts, we performed regression analysis. The same categorical variables as in previous analysis were included in Cox-proportional regression. Multivariate analysis of the prognostic variables for the development of aGVHD grade-2 to 4 and cGVHD demonstrated the independent prognostic significance of 'female donor to male recipient' as a risk factor for increased incidence of chronic GVHD (P ¼ 0.001, hazards ratio ¼ 10.296, 95% confidence interval 2.398-44.203). None of the other variables had any independent prognostic significance. Patients infused with CD34 þ cells above the median showed a trend for more cGVHD (P ¼ 0.054) ( Table 3) .
To further examine whether there is any impact of the infused CD34 þ cell dose on the incidence of GVHD, a second regression analysis was performed using the same variables except that the number of CD34 þ cells was included as a categorical variable, but with a different cutoff point (below or above the 25th percentile). Multivariate analysis showed the independent prognostic significance of 'female donor to male recipient' as a risk factor for increased incidence of cGVHD. None of the other variables had any independent prognostic significance (data not shown).
Subgroup of patients with myeloid neoplasms: the impact of graft composition on OS, NRM and RR With a median follow-up period of 49 months (range 1-139 months) 31 out of 55 patients are alive with an OS rate of 56%. Eighteen out of 55 patients died from causes not associated with the original disease, while relapse was observed in six patients. The estimated NRM and RR were 37 and 16%, respectively. OS, NRM and RR were similar between patients infused with CD34 þ cells above or below the median (10.4 Â 10 6 /kg) (P ¼ 0.766, 0.800 and 0.876, respectively).
To further examine whether there is any impact of the infused CD34 cell dose on the outcome after allo-SCT in terms of OS, NRM and RR, we divided our patients in three groups as described previously.
Patients who received less than 4.67 Â 10 6 /kg CD34 þ cells (group 1, below the 25th percentile) did not differ significantly in terms of OS (P ¼ 0.316), NRM (P ¼ 0.459) and RR (P ¼ 0.482) in from the patients in group 2 (CD34 þ cell dose above the 75th percentile). Also patients in group 1 (CD34 þ cell dose below the 25th percentile) did not differ significantly in terms of OS (P ¼ 0.701), NRM (P ¼ 0.859) and RR (P ¼ 0.649) from the patients in group 3 (CD34 þ cell dose above the 25th percentile).
Multivariate analysis did not demonstrate independent prognostic significance of any of the following variables (female donor to male recipient, related vs unrelated donor, age and number of CD34 þ cells) regarding the incidence of OS, NRM and RR (data not shown). However, multivariate analysis demonstrated the independent prognostic significance of 'disease risk status' as a risk factor for increased NRM (P ¼ 0.004) and decreased OS (P ¼ 0.001) (Figure 3) . Abbreviations: aGVHD ¼ acute graft-versus-host disease; cGVHD ¼ chronic graft-versus-host disease; CI ¼ confidence interval; HR ¼ hazards ratio. Subgroup of patients with myeloid neoplasms (n ¼ 55).
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Discussion
The use of allo-PBSC as an alternative to BM grafts has rapidly grown. Initial concerns about increased incidence of aGVHD have not been confirmed by most of the reported studies. On the contrary, the vast majority of the published studies showed increased rates of cGVHD with the use of PBSC in comparison with BM grafts. [1] [2] [3] [4] [5] [6] [7] The influence of allo-PBSC on long-term survival remains more controversial and is mainly dependent on the disease status before transplantation. Some studies reported a favorable outcome after myeloablative allo-PBSC for patients with advanced myeloid leukemias, mostly because of decreased RRs.
In the setting of myeloablative allo-PBSC, several previous studies addressed the influence of the graft composition on transplant outcome. [17] [18] [19] Although no significant association between the number of infused CD3 þ cells and incidence of GVHD was found; paradoxically they showed that the more CD34 þ cells infused, the higher the incidence of cGVHD. 18, 19 An explanation for this interesting finding remains a mystery. In elegant experiments, Reisner et al. 20 showed that donor CD34 þ cells can act as 'veto' cells and may inactivate host T-cells, with donor alloreactivity. If this is the case, then one can consider that the infusion of large numbers of CD34 þ cells helps in the elimination of the 'host-versus-graft' reaction and turns the balance in favor of the 'graft-versus-host' reaction, and thus to increased incidence of cGVHD. In previous studies it was shown that the threshold of CD34 þ cell numbers above which a deleterious increase in the incidence of cGVHD may occur, can be estimated at around 8 Â 10 6 /kg. 18, 19 The significance of the above observations is obvious, since these results, if proved, may lead to the improvement of transplant outcome simply by tailoring the composition of the graft in accordance with the patient status pre-transplant, for example, patients with high-risk disease should receive higher doses of CD34 þ cells than patients with low-risk disease and low probability of relapse.
In contrast, a very limited number of studies currently exist that address the influence of the graft composition on the outcome of allogeneic RIC. Perez-Simon et al. 21 analyzed the impact of CD34 þ cell dose on the outcome for 86 patients with hematological malignancies after allo-PBSC from matched sibling donors, using a reducedintensity regimen. Conditioning consisted of fludarabine (total dose 150 mg/m 2 ) in combination with either melphalan (140 mg/m 2 ) or BU (10 mg/kg). For GVHD prophylaxis, cyclosporine-A (CsA) plus short-term methotrexate was given. Neither CD34 þ nor CD3 þ cell dose had any effect on the incidence on aGVHD. By contrast, the dose of infused CD34 þ cells had a significant impact on the development of cGVHD. Patients transplanted with high numbers of CD34 þ cells (above the 75th percentile) had significantly more cGVHD compared with patients transplanted with lower doses. The negative impact of the increased incidence of cGVHD in patients infused with higher numbers of CD34 þ cells was offset in high-risk patients because of lower RRs.
Contrasting results were reported by Baron et al. and Panse et al. using a lower-intensity conditioning. Baron et al. 22 analyzed the impact of graft composition on the outcome of 130 patients after allogeneic NST from unrelated donors. Conditioning consisted of fludarabine (90 mg/m 2 ) in combination with low-dose TBI (2 Gy), while for GVHD prophylaxis CYA plus mycophenolate-mophetil (MMF) was given. High CD34 þ cell doses were associated with faster complete donor T-cell chimerism and reduced probability of graft rejection. The authors did not find any effect of CD34 þ or CD3 þ cell dose on incidence of aGVHD, cGVHD and RR. In a similar study, Panse et al. 23 analyzed the influence of various cell subsets contained in PBSC grafts, on the outcome for 125 patients with hematological malignancies after allo-PBSC from matched related donors. Conditioning (NST) consisted of low-dose TBI (2 Gy) alone or in combination with fludarabine (90 mg/m 2 ), while for GVHD prophylaxis CYA plus MMF was given to all the patients. Again, neither CD34 þ nor CD3 þ cell doses had any impact on the incidence of aGVHD or cGVHD, while a higher number of infused B-cells was associated with more cGVHD.
In another study, Gorin et al. examined the effect of total nucleated cell (TNC) dose and total CD34 þ cell number contained in the graft, on the outcome of 253 patients with de-novo AML, who underwent allo-PBSC from HLAidentical siblings using various RIC regimens. 24 Multivariate analysis showed that the high number of TNC was independently associated with increased leukemia-free survival in patients with high-risk disease. On the contrary, the number of CD34 þ cells did not have any significant influence on the transplant outcome. The discrepancy between the results of the above studies may be explained by the different preparative regimens. In the studies by Baron et al. and Panse et al., the intensity of the preparative regimen was lower in comparison with the conditioning used in the study performed by Perez-Simon et al.
It is generally accepted that the lower the intensity of the conditioning regimen, the lower the incidence of GVHD. 25 Preparative regimens of low intensity are associated with mild extramedullary toxicity, thus resulting in less tissue damage, especially of the gastrointestinal mucosa, hence with anticipated milder 'cytokine storm' that normally can provoke the GVHD process. 26 Taking this observation into consideration, it is reasonable to assume that in the latter studies the impact of the high CD34 þ cell doses on the GVHD was counterbalanced by an opposite impact of the lower intensity of the preparative regimen.
In our study, there was no association between the CD34 þ cell dose and the incidence of aGVHD and cGVHD. We also did not find any influence of the number of CD34 þ cells infused with the graft on OS, NRM and RR. Due to the fact that in our study we used higher CD34 þ cell doses than in the previous studies, we also examined the incidence of GVHD in subgroups of patients infused with low or high CD34 þ cell doses (below the 25th vs above the 75th percentile, and below the 25th percentile vs above the 25th percentile). Again, no significant influence on the incidence of GVHD and on transplant outcome was observed. In order to exclude the influence of any confounding variable, we performed multivariate analysis and showed that the number of infused CD34 þ cells does not have any independent significant impact on the transplant outcome and on the incidence of GVHD. In multivariate analysis, the only factor found to be associated with decreased OS was the disease risk status.
As in our study we included a large number of patients with various hematological malignancies, we decided to examine the impact of CD34 þ cell dose on the transplant outcome in a more homogenous subgroup consisting of 55 patients with myeloid neoplasms. The same analysis, as in the entire cohort of patients, was performed for the myeloid subgroup. Multivariate analysis showed that the number of CD34 þ cells did not have any independent significant impact on the incidence of aGVHD, cGVHD, as well as on the transplant outcome. As in previous analysis, multivariate analysis revealed that the only factor found to be associated with decreased OS was the disease risk status.
The results of our study are different from those reported by the study of Perez-Simon et al., despite the fact that in both studies the preparative regimens were of similar intensity. In contrast with the previous study, ATG was included in our conditioning regimen. Previous studies have shown a beneficial effect of pre-transplant administration of ATG in reducing cGVHD and NRM, with a modest increase in OS, in patients receiving myeloablative conditioning. 27 This issue is as yet unresolved in the setting of allogeneic RIC, and prospective randomized studies evaluating the effect of ATG administration on the transplant outcome are currently underway. However, it seems reasonable to consider that inclusion of ATG with its anti-GVHD effect may have ameliorated the negative impact of the high doses of CD34 þ cells on the incidence of cGVHD.
In another study, Spyridonidis et al. 28 described their experience using a novel, reduced-toxicity regimen on 34 patients older than 60 years and with various myeloid neoplasms. The conditioning consisted of carmustine, fludarabine, melphalan and ATG (Fresenius). All patients received PBSC from matched unrelated donors. Similar to our study, the authors did not find any significant impact of the number of CD34 þ cells infused with the graft, on the incidence of cGVHD. However, in contrast to our results, they observed that the group of patients who received CD34 þ cell dose above the median (8 Â 10 6 /kg) had improved OS in comparison with patients who received a CD34 þ cell dose below the median.
In conclusion, we consider that the influence of graft composition in the setting of allogeneic RIC should be further investigated with well-controlled, randomized, prospective studies. The results of these studies are extremely important, as tailoring the dose of the different cell subsets contained in the graft to each individual patient might improve the transplant outcome.
